Review



decitabine  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    MedChemExpress decitabine
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    Decitabine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 161 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/decitabine/product/MedChemExpress
    Average 96 stars, based on 161 article reviews
    decitabine - by Bioz Stars, 2026-03
    96/100 stars

    Images

    1) Product Images from "SLC46A1 deficiency-mediated folate restriction suppresses colorectal cancer progression through epigenetic-transcriptional reprogramming"

    Article Title: SLC46A1 deficiency-mediated folate restriction suppresses colorectal cancer progression through epigenetic-transcriptional reprogramming

    Journal: Cell Death & Disease

    doi: 10.1038/s41419-026-08423-8

    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. Decitabine (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    Figure Legend Snippet: A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. Decitabine (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).

    Techniques Used: Transfection, DNA Methylation Assay, CpG Methylation Assay, Knockdown, Enzyme-linked Immunosorbent Assay, Next-Generation Sequencing



    Similar Products

    decitabine  (MedChemExpress)
    96
    MedChemExpress decitabine
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    Decitabine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/decitabine/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    decitabine - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    hy a0004r  (MedChemExpress)
    96
    MedChemExpress hy a0004r
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    Hy A0004r, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hy a0004r/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    hy a0004r - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    hy a0004  (MedChemExpress)
    96
    MedChemExpress hy a0004
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    Hy A0004, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hy a0004/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    hy a0004 - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    aza cdr dac  (MedChemExpress)
    96
    MedChemExpress aza cdr dac
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    Aza Cdr Dac, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aza cdr dac/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    aza cdr dac - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    5 aza cdr dac  (MedChemExpress)
    96
    MedChemExpress 5 aza cdr dac
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    5 Aza Cdr Dac, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/5 aza cdr dac/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    5 aza cdr dac - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    5 aza cdr  (MedChemExpress)
    96
    MedChemExpress 5 aza cdr
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    5 Aza Cdr, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/5 aza cdr/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    5 aza cdr - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich  (MedChemExpress)
    96
    MedChemExpress ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich
    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. <t>Decitabine</t> (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).
    Ladakamycin Medchemexpress Hy 10586r Decitabine Medchemexpress Hy A0004r Arsenic Trioxide Sigma Aldrich, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    ladakamycin medchemexpress hy 10586r decitabine medchemexpress hy a0004r arsenic trioxide sigma aldrich - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. Decitabine (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).

    Journal: Cell Death & Disease

    Article Title: SLC46A1 deficiency-mediated folate restriction suppresses colorectal cancer progression through epigenetic-transcriptional reprogramming

    doi: 10.1038/s41419-026-08423-8

    Figure Lengend Snippet: A Reactome enrichment analysis of changed pathways in SLC46A1-downregulated HCT8 cells. B Heatmap of the altered genes in HCT8 cells inhibiting SLC46A1 compared with negative controls. C , D FOS mRNA and protein levels after shSLC46A1 transfection in DiFi and HCT8 cells. E , F FOS mRNA and protein levels in SLC46A1-inhibited cells treated with folate or PBS. G Global 5-mC levels in SLC46A1-downregulated DiFi and HCT8 cells. H Global 5-mC levels in DiFi and HCT8 cells treated with folate or PBS. I FOS mRNA levels in DiFi and HCT8 cells treated with folate and DAC or DMSO. J CpG island prediction in the FOS promoter region using MethPrimer; changes in FOS promoter DNA methylation (left) and quantitative analysis of CpG methylation within Area 1 of the FOS promoter after SLC46A1 knockdown (right). Bar plot data are expressed as the mean ± SD. Significant differences were assessed by one-way ANOVA ( C , I ) or Student’s t tests ( E , G , H , J right). * p < 0.05, ** p < 0.01, *** p < 0.001. Decitabine (DAC), Enzyme-linked immunosorbent assay (ELISA), 5-methylcytosine (5-mC), next-generation sequencing bisulfite pyrosequencing (NGS-BSP).

    Article Snippet: Cells were treated with 5 μM decitabine (MedChemExpress) for demethylation experiments.

    Techniques: Transfection, DNA Methylation Assay, CpG Methylation Assay, Knockdown, Enzyme-linked Immunosorbent Assay, Next-Generation Sequencing